{
  "ticker": "CHM",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959004",
  "id": "02959004",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250617",
  "time": "0829",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250617/pdf/06kt6st9534k2w.pdf",
  "summary": "**Summary of ASX Announcement (Clinical Trial Update - Translational Data):**  \n\n- **CHM CDH17 CAR-T cells** demonstrated persistence up to **6 months post-infusion** in 2/4 subjects at **Dose Level 1** (phase 1/2 trial).  \n- **Target validation:** Cadherin 17 (CDH17) confirmed on tumour cells in all subjects.  \n- **Trial progress:** Dose Level 2 enrolment ongoing; Phase 1 aims to enrol up to **15 patients**.  \n- **Trial design:** Phase 1/2 focuses on **advanced GI cancers** (colorectal, gastric, neuroendocrine tumours).  \n\n**No material financial/capital impact identified**. Pure clinical update with no fundraising, timelines, or operational metrics.",
  "usage": {
    "prompt_tokens": 1276,
    "completion_tokens": 165,
    "total_tokens": 1441,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-16T22:38:48.414677"
}